• 1_IMG_4168.jpg
  • 3_IMG_4168.jpg

To download the press release, please click here.

 

Accelero Launches EliSpot & FluoroSpot GLP Lab Services

Berlin, February 05, 2018

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development, and maintains biosafety level 2 laboratories in compliance with ICH GCP regulations.

The company is pleased to launch the most sensitive immunoassays currently available on the market. The Enzyme-Linked ImmunoSpot (EliSpot) assay monitors cellular immune response upon stimulation with antigens of interest like monoclonal antibodies, oncolytic viruses, drug product formulations, or even living biotherapeutics like human stem cells or bacterial cells.

Accelero now provides the complete series of routine antibody detection assays (screening, confirmation, neutralization) for primary immunological drug characterization. T-cell or B-cell mediated cytokine secretion can also be detected after isolation from pre-clinical or clinical whole blood samples.

The computerized system can analyse 96-well and 384-well assay plates after standard chromogenic (EliSpot) or 3-colour fluorescence staining (FluoroSpot). The instrument is equipped with a two megapixel camera, and excitation/emission filters for FITC (Alexa488), Cy3, and Cy5 (Alexa647) for parallel staining and detection.

Please follow this link for additional information on our cell-based immunoassays, or use our contact form. Please feel free to send us an email to service(at)accelero-bioanalytics.com. The Accelero team will be happy to assist you.

 

To download the press release, please click here.

 

Accelero Sees 23% Sales Revenue Increase in 2017 - 9% Operating Profit Margin

Berlin, January 17, 2018

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development, and maintains biosafety level 2 laboratories in compliance with ICH GCP regulations.

The company is pleased to announce the successful closing of the fiscal year 2017. In comparison to the previous year, the sales revenue increased by 23% (in 2016: 57%).

Accelero´s benchmarking services for advanced therapies based on human cells, microbial cells, as well as viral vectors are widely recognized. Numerous non-clinical and clinical studies have been performed to support the development of Advanced Therapy Medicinal Products (ATMP) for Accelero´s international clients from seven countries.

The operating profit margin could be increased to 9% of the sales revenues (in 2016: 5.9%). 100% of the revenues have been reinvested in the company to sustain Accelero´s growth.

The annual financial statement will soon be published in the German Bundesanzeiger.

Accelero would like to thank its clients for their trust and confidence in the services.

A special word of thanks goes to all “Acceleros” in the team – without a dedicated team spirit this positive company development would not have been possible!

The team is looking forward forming a symbiotic relationship to innovative customers developing groundbreaking living therapies.